MintNeuro, a pioneer of low-power semiconductor technology for minimally-invasive neural implant applications, has raised £1 million funding.
Neurological disorders impact over a billion people globally but current treatments are often ineffective or fail to provide long-term solutions.
Neural implants offer a promising alternative, yet traditional technologies remain bulky, power-intensive and reliant on invasive surgeries that limit accessibility and increase patient risk.
Developed at Imperial College London, MintNeuro aims to use semiconductor technology to make neural implants smaller, more efficient and scalable.
With over £14m in R&D grant funding to date, its compact, low-power chips enable modular designs adaptable to various neurological conditions.
The funding round was led by Empirical Ventures. Additional investment came from Parkwalk Advisors (through the Imperial College Enterprise Fund), Imperial College London, Plug & Play, Excellis Holding, and several prominent angel investors.
“Our semiconductor-based approach is fundamentally reshaping what neural implants can achieve,” said Timothy Constandinou, CTO and co-founder.
“By offering a customisable, compact solution that integrates seamlessly into medical devices, we’re empowering a new era of neural interfaces that are not only more powerful but also less invasive. This marks a transformative shift in neurological care.”
Cancer & dementia battle boost as UK genetics partnership signed
MintNeuro’s innovative semiconductor solutions have already gained considerable traction through strategic partnerships with leading institutions and medical device companies.
Collaborations include the NIHR-funded DREAM project with Imperial College London and King’s College London and Hospital, targeting development of a breakthrough device for epilepsy monitoring, with a first-in-human study planned for next year.
Additionally, MintNeuro’s partnership with Amber Therapeutics, which has recently secured $100m in funding, is focused on developing a neuromodulation therapy chipset through an Innovate UK Smart grant.
This technology initially targets mixed urinary incontinence, with the potential for future applications of the MintNeuro chipset in conditions such as Parkinson’s disease, dementia, and depression.
“Millions of patients with neurological disorders face limited treatment options,” said Dorian Haci, CEO and co-founder. “Our goal is to bridge that gap with safer, more accessible, and effective neural technology.
“This investment accelerates our chip development and enables us to expand our team of experts, bringing game-changing neural implants to clinicians for the benefit of patients everywhere.”